Arabic Arabic English English French French German German
dark

GenSight Biologics Appoints Country Leads for France, Germany and the UK in Preparations for LUMEVOQ® Commercial Launch

GenSight Biologics, a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced that the Company’s country leads for three key European markets are in place. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Applied UV and 3Sixty Biopharmaceuticals Sign Exclusive Distribution Agreement for Airocide(R) Air Purification Systems for the Continent of Africa

Next Post

With 80,000 Participants, the Largest Study of Its Kind Is the First to Evaluate the Benefits of Screening for a Precursor to the Blood Cancer Multiple Myeloma

Related Posts
Total
0
Share